Volume reduction device for left ventricle

Abstract

The invention provides a volume reduction device for a left ventricle. The volume reduction device comprises a supporting frame which is made of shape memory alloy, and the supporting frame is covered with a polymeric membrane. When the supporting frame is released into the left ventricle from the cardiac apex of the left ventricle, the shape of the released supporting frame is matched with the inner wall of the left ventricle. A supporting end which extends outwards is arranged at the end, far away from the cardiac apex, of the supporting frame, and the supporting end is clamped on the inner wall of the left ventricle. A connecting sleeve which is detachably connected with a push rod is arranged at the end, close to the cardiac apex, of the supporting frame. According to the volume reduction device for the left ventricle, the ventricle area without functions can be isolated, the volume contraction and expansion are reduced, the tension of the left ventricle is lowered, and the cardiac function of left ventricle reconstitution and heart failure patients is improved. An intervention way is adopted, the design of minimally invasive cardiac apex passing is created, and the trauma is lowered to the minimum. Through the design that the diameter of a transferring sheath is decreased in the cardiac apex passing way or the intervention way, the risk of damaging blood vessels, cardiac valves and the like is avoided. The design of a positioning base, a cardiac apex positioner and the like is adopted, positioning is good, and the attaching tension is high.

Description

technical field [0001] The invention relates to a left ventricle volume reduction device. Background technique [0002] Heart failure is the end result of most cardiovascular diseases and the leading cause of death, affecting nearly 23 million people worldwide. Parachute is the first percutaneous left ventricular reconstruction device designed based on catheter technology. This technology was first reported in 2007, and then gradually developed abroad, accumulating experience in hundreds of cases, and obtained European CE certification in 2011. Results It has been shown that it can effectively relieve the clinical symptoms of patients with heart failure, improve heart function, and increase the five-year survival rate of patients with advanced heart failure from 30% to 80%. It has been used in more than 500 cases in Europe and America. [0003] The prevalence rate of heart failure is 0.9% in China and 1.4% in the northern region, and there are about 4 million heart failure ...

Images